Insider Sells 300,000 Macy's Shares; New 50,000-Share Notice Filed

Rhea-AI Filing Summary

Macy's, Inc. Form 144 reports a proposed sale of 50,000 shares of common stock to be executed on 09/18/2025 through Charles Schwab, with an aggregate market value of $870,000.00. The filing shows these 50,000 shares were acquired in March 2023 through restricted/performance stock vesting. The notice also discloses sales by the same person in the prior three months totaling 250,000 shares for gross proceeds of $4,379,527.03 (sales on 09/05/2025, 09/11/2025, and 09/17/2025). The issuer's outstanding shares are listed as 268,505,751. By signing, the seller represents they do not possess undisclosed material adverse information about the issuer.

Positive

• Transparent disclosure of proposed sale date, broker, acquisition dates, and amounts consistent with Rule 144 requirements
• Acquisitions were from compensation (restricted/performance stock vesting), clearly noted in the filing
• Seller attests they do not possess undisclosed material adverse information, supporting compliance

Negative

• Recent insider dispositions are sizable in absolute terms: 250,000 shares sold in the prior three months for gross proceeds of $4,379,527.03
• Proposed additional sale of 50,000 shares ($870,000) further increases insider liquidity in a short period

Insights

Securities Analyst

TL;DR: Routine insider sale filings show recent multiple dispositions totaling 300,000 shares including the proposed 50,000-share sale, signaling notable insider liquidity but not necessarily firm-level impact.

The filing documents a proposed sale of 50,000 Macy's shares (aggregate value $870,000) acquired via restricted/performance stock vesting in March 2023. Combined with three prior reported sales in September totaling 250,000 shares for $4,379,527.03, the insider has disclosed significant recent disposals. Relative to the 268.5 million shares outstanding, these transactions represent a small ownership change by percentage terms. This filing is consistent with compliance with Rule 144 and standard reporting of director/officer or affiliate sales; it provides transparency on timing, broker, and acquisition source but contains no operational or financial performance details about Macy's itself.

Corporate Compliance/Risk Analyst

TL;DR: The Form 144 appears complete for a Rule 144 notice, showing acquisition details and recent sales; the signer affirms no undisclosed material information.

The document includes required acquisition details (dates in March 2023 and nature as restricted/performance vesting), planned sale mechanics (broker and date), and recent sales history over the past three months. The signature representation that no material nonpublic information exists is standard and important for compliance. There is no indication in this notice of any trading plan adoption date or 10b5-1 instructions, and the filing does not include any disclosure of material corporate events, litigation, or financial metrics that would affect valuation. From a compliance perspective, the form satisfies disclosure elements specific to proposed sales under Rule 144.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Charles Schwab & Co. 211 Main Street San Francisco CA 94105	50000	870000.00	268505751	09/18/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/23/2023	Performance Restricted Stock Vesting	Macy's, Inc.			44081	03/23/2023	Compensation
Common Stock	03/24/2023	Restricted Stock Vesting	Macy's, Inc.			4179	03/24/2023	Compensation
Common Stock	03/25/2023	Restricted Stock Vesting	Macy's, Inc.			1740	03/25/2023	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Danielle L. Kiegan c/o Macy's, Inc. 151 West 34th Street New York NY 10001	Common Stock	09/05/2025	100000	1729527.03
Danielle L. Kirgan c/o Macy's, Inc. 151 West 34th Street New York NY 10001	Common Stock	09/11/2025	50000	875000.00
Danielle L. Kirgan c/o Macy's, Inc. 151 West 34th Street New York NY 10001	Common Stock	09/17/2025	100000	1775000.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Macy's (M) Form 144 report?

The filing reports a proposed sale of 50,000 Macy's common shares to occur on 09/18/2025 via Charles Schwab, with aggregate market value of $870,000.00.

Who acquired the shares being sold and how were they acquired?

The 50,000 shares were acquired in March 2023 through restricted stock and performance restricted stock vesting from Macy's, Inc., with acquisition dates 03/23/2023, 03/24/2023, and 03/25/2023.

Has the seller made other Macy's stock sales recently?

Yes. The filing lists sales in the past three months totaling 250,000 shares on 09/05/2025, 09/11/2025, and 09/17/2025 for combined gross proceeds of $4,379,527.03.

How many Macy's shares are outstanding according to this filing?

The filing lists 268,505,751 shares outstanding.

Does the filing indicate any undisclosed material information?

By signing, the person filing represents they do not know any material adverse information about Macy's that has not been publicly disclosed.

Which broker is handling the proposed sale?

The proposed sale is to be handled by Charles Schwab & Co., 211 Main Street, San Francisco, CA 94105.